全文获取类型
收费全文 | 1229篇 |
免费 | 83篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 27篇 |
妇产科学 | 34篇 |
基础医学 | 158篇 |
口腔科学 | 16篇 |
临床医学 | 91篇 |
内科学 | 282篇 |
皮肤病学 | 7篇 |
神经病学 | 153篇 |
特种医学 | 36篇 |
外科学 | 131篇 |
综合类 | 3篇 |
预防医学 | 73篇 |
眼科学 | 9篇 |
药学 | 57篇 |
中国医学 | 1篇 |
肿瘤学 | 235篇 |
出版年
2023年 | 6篇 |
2022年 | 24篇 |
2021年 | 31篇 |
2020年 | 19篇 |
2019年 | 32篇 |
2018年 | 38篇 |
2017年 | 32篇 |
2016年 | 30篇 |
2015年 | 30篇 |
2014年 | 46篇 |
2013年 | 60篇 |
2012年 | 80篇 |
2011年 | 95篇 |
2010年 | 40篇 |
2009年 | 43篇 |
2008年 | 52篇 |
2007年 | 60篇 |
2006年 | 41篇 |
2005年 | 53篇 |
2004年 | 57篇 |
2003年 | 50篇 |
2002年 | 39篇 |
2001年 | 53篇 |
2000年 | 43篇 |
1999年 | 34篇 |
1998年 | 14篇 |
1997年 | 8篇 |
1996年 | 14篇 |
1995年 | 11篇 |
1994年 | 10篇 |
1993年 | 7篇 |
1992年 | 22篇 |
1991年 | 21篇 |
1990年 | 16篇 |
1989年 | 14篇 |
1988年 | 22篇 |
1987年 | 8篇 |
1986年 | 11篇 |
1985年 | 3篇 |
1984年 | 7篇 |
1983年 | 3篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1974年 | 5篇 |
1973年 | 2篇 |
1972年 | 4篇 |
1967年 | 3篇 |
1966年 | 3篇 |
1964年 | 2篇 |
排序方式: 共有1316条查询结果,搜索用时 15 毫秒
41.
Alberto Bedogni Stefano Fedele Giorgio Bedogni Matteo Scoletta Gianfranco Favia Giuseppe Colella Alessandro Agrillo Giordana Bettini Olga Di Fede Giacomo Oteri Vittorio Fusco Mario Gabriele Livia Ottolenghi Stefano Valsecchi Stephen Porter Massimo Petruzzi Paolo Arduino Salvatore D’Amato Claudio Ungari Pok-Lam Fung Polly Giorgia Saia Giuseppina Campisi 《The British journal of oral & maxillofacial surgery》2014
Management of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity of disease is the main guide to management, and can help to predict prognosis. Most available staging systems for osteonecrosis, including the widely-used American Association of Oral and Maxillofacial Surgeons (AAOMS) system, classify severity on the basis of clinical and radiographic findings. However, clinical inspection and radiography are limited in their ability to identify the extent of necrotic bone disease compared with computed tomography (CT). We have organised a large multicentre retrospective study (known as MISSION) to investigate the agreement between the AAOMS staging system and the extent of osteonecrosis of the jaw (focal compared with diffuse involvement of bone) as detected on CT. We studied 799 patients with detailed clinical phenotyping who had CT images taken. Features of diffuse bone disease were identified on CT within all AAOMS stages (20%, 8%, 48%, and 24% of patients in stages 0, 1, 2, and 3, respectively). Of the patients classified as stage 0, 110/192 (57%) had diffuse disease on CT, and about 1 in 3 with CT evidence of diffuse bone disease was misclassified by the AAOMS system as having stages 0 and 1 osteonecrosis. In addition, more than a third of patients with AAOMS stage 2 (142/405, 35%) had focal bone disease on CT. We conclude that the AAOMS staging system does not correctly identify the extent of bony disease in patients with osteonecrosis of the jaw. 相似文献
42.
Michael J Fusco Todd C Knepper Juliana Balliu Alex Del Cueto Jose M Laborde Sharjeel M Hooda Andrew S Brohl Marilyn M Bui J Kevin Hicks 《The oncologist》2022,27(1):e9
BackgroundCancer of unknown primary (CUP) comprises a heterogeneous collection of malignancies that are typically associated with a poor prognosis and a lack of effective treatment options. We retrospectively evaluated the clinical utility of targeted next-generation sequencing (NGS) among CUP patients to assist with diagnosis and identify opportunities for molecularly guided therapy.Patients and MethodsPatients with a CUP at Moffitt Cancer Center who underwent NGS between January 1, 2014 and December 31, 2019, were eligible for study inclusion. Next-generation sequencing results were assessed to determine the frequency of clinically actionable molecular alterations, and chart reviews were performed to ascertain the number of patients receiving molecularly guided therapy.ResultsNinety-five CUP patients were identified for analysis. Next-generation sequencing testing identified options for molecularly guided therapy for 55% (n = 52) of patients. Among patients with molecularly guided therapy options, 33% (n = 17) were prescribed a molecularly guided therapy. The median overall survival for those receiving molecularly guided therapy was 23.6 months. Among the evaluable patients, the median duration of treatment for CUP patients (n = 7) receiving molecular-guided therapy as a first-line therapy was 39 weeks. The median duration of treatment for CUP patients (n = 8) treated with molecularly guided therapy in the second- or later-line setting was 13 weeks. Next-generation sequencing results were found to be suggestive of a likely primary tumor type for 15% (n = 14) of patients.ConclusionNext-generation sequencing results enabled the identification of treatment options in a majority of patients and assisted with the identification of a likely primary tumor type in a clinically meaningful subset of patients. 相似文献
43.
Doreen A. Ezeife MD Francois Dionne PhD Aline Fusco Fares MD Ellen Laura Rose Cusano MD Rouhi Fazelzad BSc MISt Wenzie Ng BSc MPharm RPh Don Husereau BSc Pharm MSc Farzad Ali BPharm MSc Christina Sit MSc Barry Stein B.Com BCL LLB Jennifer H. Law MSc Lisa Le MSc Peter Michael Ellis MD MMed PhD Scott Berry MD Stuart Peacock PhD Craig Mitton PhD Craig C. Earle MD Kelvin K. W. Chan MD PhD Natasha B. Leighl MD MMSc 《Cancer》2020,126(7):1530-1540
44.
Jane Wolstenholme Francesco Fusco Alastair M. Gray Joanna Moschandreas Pradeep S. Virdee Sharon Love Guy Van Hazel Peter Gibbs Harpreet S. Wasan Ricky A. Sharma 《International journal of cancer. Journal international du cancer》2020,147(4):1078-1085
Selective internal radiotherapy (SIRT) is a liver-directed treatment involving the injection of yttrium-90 microspheres into the blood supply of liver tumours. There are very few studies assessing health-related quality of life (HRQOL) in patients treated with SIRT. Patients with liver metastases from colorectal cancer (CRC) were randomised in the FOXFIRE (FFr; ISRCTN83867919), SIRFLOX (SF; NCT00724503) and FOXFIRE-Global (FFrG; NCT01721954) trials of first-line oxaliplatin–fluorouracil (FOLFOX) chemotherapy combined with SIRT versus FOLFOX alone. HRQOL was assessed using the three-level EQ-5D, European Organisation for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and EORTC Colorectal Liver Metastases cancer module (EORTC QLQ-LMC21) at baseline, ≤3 months, 6 months, 12 months and annually thereafter from randomisation, and at disease progression. Analyses were conducted on an intention-to-treat basis. In total, 554 patients were randomised to SIRT + FOLFOX and 549 patients to FOLFOX alone. HRQOL was statistically significant lower in SIRT + FOLFOX patients ≤3 months after SIRT administration in all three instruments, particularly global health, physical and role functioning and symptoms of fatigue, nausea/vomiting and appetite loss. By accepted thresholds, these differences were deemed not clinically important. Differences between SIRT + FOLFOX and FOLFOX alone over the 2-year follow up and at disease progression were also not clinically important. Although there is some decrease in HRQOL for up to 3 months following SIRT, the addition of SIRT to FOLFOX chemotherapy does not change HRQOL to a clinically important degree in metastatic CRC patients. 相似文献
45.
Long noncoding RNAs have been recently demonstrated to have an important role in fundamental biological processes, and their deregulated expression has been found in several human neoplasias. Our group has
recently reported a drastic overexpression of the long noncoding RNA (lncRNA) RPSAP52 (ribosomal protein SA pseudogene 52) in pituitary adenomas. We have shown that this lncRNA increased cell proliferation
by upregulating the expression of the chromatinic proteins HMGA1 and HMGA2, functioning as a competing endogenous RNA (ceRNA) through competitively binding to microRNA-15a (miR-15a), miR-15b, and
miR-16. The aim of this work was to identify further mechanisms by which RPSAP52 overexpression could
contribute to the development of pituitary adenomas. We investigated the involvement of RPSAP52 in the
modulation of the expression of cell cycle-related genes, such as p21Waf1/CIP, whose deregulation plays a
critical role in pituitary cell transformation. We report that RPSAP52, interacting with the RNA binding protein
HuR (human antigen R), favors the delocalization of miR-15a, miR-15b, and miR-16 on the cyclin-dependent
kinase inhibitor p21Waf1/CIP1 that, accordingly, results in downregulation in pituitary adenomas. A RNA
immunoprecipitation sequencing (RIPseq) analysis performed on cells overexpressing RPSAP52 identified 40
messenger RNAs (mRNAs) enriched in Argonaute 2 (AGO2) immunoprecipitated samples. Among them, we
focused on GAS8 (growth arrest-specific protein 8) gene. Consistently, GAS8 expression was downregulated
in all the analyzed pituitary adenomas with respect to normal pituitary and in RPSAP52-overepressing cells,
supporting the role of RPSAP52 in addressing genes involved in growth inhibition and cell cycle arrest to
miRNA-induced degradation. This study unveils another RPSAP52-mediated molecular mechanism in pituitary tumorigenesis. 相似文献
46.
47.
Arturo Ciccullo Gianmaria Baldin Vanni Borghi Filippo Lagi Alessandra Latini Gabriella dEttorre Letizia Oreni Paolo Fusco Amedeo Capetti Massimiliano Fabbiani Andrea Giacomelli Alessandro Grimaldi Giordano Madeddu Gaetana Sterrantino Cristina Mussini Simona Di Giambenedetto 《Viruses》2022,14(1)
Dolutegravir (DTG) is currently one of the most used Integrase inhibitors (INI) in antiretroviral therapies (ARV) in both naïve and experienced people living with HIV (PLWHIV). We analyzed a multicenter cohort of PLWHIV, both naïve and experienced, starting an ARV including DTG. We enrolled 3775 PLWHIV: 2763 (73.2%) were males, with a median age of 50 years. During 9890.7 PYFU, we observed 930 discontinuations (9.4 per 100 PYFU). Estimated probabilities of maintaining DTG at three and five years were 75.1% and 67.2%, respectively. Treatment-naïve pts showed a lower probability of maintaining DTG at three and five years compared to treatment-experienced PLWHIV (log-rank p < 0.001). At a multivariate analysis, a longer time of virological suppression (aHR 0.994, p < 0.001) and having experienced a previous virological failure (aHR 0.788, p = 0.016) resulted protective against DTG discontinuation. Most discontinuations (84.0%) happened within the first 12 months of DTG initiation, in particular, 92.2% of discontinuations due to neuropsychiatric toxicity were observed in the first year. Our data confirm the overall good tolerability of DTG in clinical practice, with a low rate of discontinuations. CNS toxicity resulted the main reason for DTG discontinuation, with most related interruptions happening in the first year from DTG introduction. 相似文献
48.
Alessandro de Sire Luca Gallelli Nicola Marotta Lorenzo Lippi Nicola Fusco Dario Calafiore Erika Cione Lucia Muraca Antonio Maconi Giovambattista De Sarro Antonio Ammendolia Marco Invernizzi 《Nutrients》2022,14(8)
Breast cancer (BC) is the most frequent malignant tumor in women in Europe and North America, and the use of aromatase inhibitors (AIs) is recommended in women affected by estrogen receptor-positive BCs. AIs, by inhibiting the enzyme that converts androgens into estrogen, cause a decrement in bone mineral density (BMD), with a consequent increased risk of fragility fractures. This study aimed to evaluate the role of vitamin D3 deficiency in women with breast cancer and its correlation with osteoporosis and BMD modifications. This observational cross-sectional study collected the following data regarding bone health: osteoporosis and osteopenia diagnosis, lumbar spine (LS) and femoral neck bone mineral density (BMD), serum levels of 25-hydroxyvitamin D3 (25(OH)D3), calcium and parathyroid hormone. The study included 54 women with BC, mean age 67.3 ± 8.16 years. Given a significantly low correlation with the LS BMD value (r2 = 0.30, p = 0.025), we assessed the role of vitamin D3 via multiple factor analysis and found that BMD and vitamin D3 contributed to the arrangement of clusters, reported as vectors, providing similar trajectories of influence to the construction of the machine learning model. Thus, in a cohort of women with BC undergoing Ais, we identified a very low prevalence (5.6%) of patients with adequate bone health and a normal vitamin D3 status. According to our cluster model, we may conclude that the assessment and management of bone health and vitamin D3 status are crucial in BC survivors. 相似文献
49.
Federico Zara Nicola Specchio Pasquale Striano Angela Robbiano Elena Gennaro Roberta Paravidino Nicola Vanni Francesca Beccaria Giuseppe Capovilla Amedeo Bianchi Lorella Caffi Viviana Cardilli Francesca Darra Bernardo Dalla Bernardina Lucia Fusco Roberto Gaggero Lucio Giordano Renzo Guerrini Gemma Incorpora Massimo Mastrangelo Luigina Spaccini Anna Maria Laverda Marilena Vecchi Francesca Vanadia Pierangelo Veggiotti Maurizio Viri Guya Occhi Mauro Budetta Maurizio Taglialatela Domenico A. Coviello Federico Vigevano Carlo Minetti 《Epilepsia》2013,54(3):425-436
50.